MEDICAL HEALTH SCREENING SERVICES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)
Medical Health Screening Services Market, By Test Type (Routine Tests, Non-Routine Tests, Cancer Screening Tests, Specialty Tests, and Others), By Setting Type (Hospitals/Clinical Laboratories, Workplaces, Ambulatory Care Centers, Multi-specialty Clinics, Diagnostic Imaging Centers, and Others), By Sample Type (Blood, Urine, Saliva, and Others), By End User (Hospitals/Clinics, Diagnostic Laboratories, Workplaces, Research Institutes, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
In May 2023, Index Medical Systems, a healthcare company received regulatory approval from the National Medical Products Administration (NMPA), China to launch over 30 medical tests in the areas of oncology, women's health, and general wellness screening in China. These will allowIndex to tap into China's large preventive healthcare screening industry and provide quality healthcare services to more Chinese citizens.
In July 2022, Bloom Diagnostics, a medtech startup launched its new Bloom Inflammation Test, which measures C-reactive protein (CRP) in the bloodstream to detect inflammation in the body.
In May 2022, QIAGEN NV, provider of sample and assay technologies for molecular diagnostics launched the QIAstat Dx Rise and advanced panels. QIA stat-Dx Rise and its test cartridges are a closed system for manual sample preparation and processing.
In January 2022, health screening provider Practo, a mhealth platform launched diabetes screening services across various cities in India. Practo started providing HbA1c, fasting and post-meal blood sugar screening at affordable prices through a network of partner labs. This expanded Practo's preventive health screening portfolio and enabled more accessibility to diabetes screening services in India.
In June 2021, Grail, a healthcare company introduced the Galleri diagnostic, a single blood test capable of detecting the presence of numerous malignancies. The test is intended to check patients who are already at a high risk of cancer, such as persons over the age of 50.